Malaysia
Furthermore, the rise in the geriatric population of Malaysia is another factor associated with non-communicable diseases. According to a declaration made by Malaysia's Chief Statistician in July 2019, there will be an increase of 15% in the current geriatric population by 2030. Malaysia's age distribution has changed during the last ten years. The percentage of people aged 0 to 14 has been rapidly declining, but the opposite was true for people 65 and older. This trend was reflected by the average age of the Malaysian population, which was projected to rise from 28.2 years in 2015 to 34.1 years in 2030. Due to changes in dietary habits, poor dentition, and amounts of food consumed, malnutrition is also a major problem in the elderly of the nation. The growing aging population and the rise of non-communicable diseases in the country will lead to more visits to diagnostic centers for disease diagnosis before hospitalization, enhancing the growth of the Malaysia diagnostic labs market.
Use of Digital Pathology to Augment Pathological Diagnosis
Digital pathology
Growth in Medical Tourism
Malaysia is now considered one of Asia's most perceived emerging nations for
Demand of Genetic Testing
Expanding interest in genetic testing also drives the market. Genetic testing helps patients make significant choices in the treatment or early discovery of genetic problems. The high occurrence rate of irresistible illnesses in Malaysia, as well as developing attention to the significance of early diagnosis and accuracy in test analysis, is expanding the patients' visits to diagnostic laboratories for testing.
Government Initiatives for Investment in Healthcare Sector
Malaysia's government plans to advance market development by investing in multiple sectors like developing drug and diagnostic tools, clinical research facilities, and diagnostic laboratories. A-Bio has contributed a whooping amount of USD1.8 million to Clinipath Malaysia Sdn. Bhd. (Clinipath) to catalyze the digitalization of the medical care industry in Malaysia. Malaysia has a strategy of all-inclusive wellbeing inclusion. The public authority/government plans to give sponsored medical care at minimum charges. The sponsored plans are looked after and managed by the Ministry of Health (MOH) through its government, state, and local offices. General health check-ups conducted by the government of Malaysia are on the rise, presenting a possible chance of market growth.
DOWNLOAD FREE SAMPLE REPORT
Market Segmentation
The Malaysia diagnostic labs
Company Profiles
Pantai Premier Pathology Sdn Bhd, Sunway Medical Centre, Lablink (M) Sdn Bhd, Pathology & Clinical Laboratory (M) Sdn. Bhd., Quantum Diagnostics Sdn Bhd, B.P. Clinical Lab Sdn. Bhd. (BP Lab), Innoquest Pathology, Clinipath Malaysia Sdn. Bhd., Neogenix Laboratoire Sdn Bhd, Sysmex Malaysia Sdn. Bhd.
Attribute | Details |
Market size value in 2021 | USD1011.24 Million |
Revenue Forecast in 2027 | USD1643.30 Million |
Base Year | 2021 |
Historical Years | 2017 – 2021 |
Estimated Year | 2022 |
Forecast Period | 2023 – 2027 |
Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022E-2027F |
Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered | · Provider Type · Test Type · End User |
Regional Scope | West; East |
Key Companies Profiled | Pantai Premier Pathology Sdn Bhd, Sunway Medical Centre, Lablink (M) Sdn Bhd, Pathology & Clinical Laboratory (M) Sdn. Bhd., Quantum Diagnostics Sdn Bhd, B.P. Clinical Lab Sdn. Bhd. (BP Lab), Innoquest Pathology, Clinipath Malaysia Sdn. Bhd., Neogenix Laboratoire Sdn Bhd, Sysmex Malaysia Sdn. Bhd. |
Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request) |